Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma.
Extranodal natural killer/T-cell lymphoma, nasal type (ENKL), is a rare subtype of non-Hodgkin lymphoma, and its treatment outcome was previously poor. Novel treatment strategies have improved the outcomes of ENKL remarkably in the last decade. Nowadays, patients with localized nasal ENKL are recommended treatment with concurrent chemoradiotherapy, and their 5-year overall survival rate is approximately 70%. In patients with advanced or relapsed/refractory disease, the efficacy of l-asparaginase-containing therapy has been confirmed. However, there still remain unmet needs in the treatment of ENKL. Continued efforts should be made to further improvements in the treatment of ENKL.
Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Electronic address: smakita@ncc.go.jp.
Shinichi
S
Makita
Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Kensei
K
Tobinai
D059248:Chemoradiotherapy / Q000009:adverse effects / Q000379:methods*; D018572:Disease-Free Survival; D054391:Lymphoma, Extranodal NK-T-Cell / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy; D009669:Nose Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy; D015996:Survival Rate
CCRT; DeVIC; EBV; ENKL; Extranodal NK/T-cell lymphoma; Lymphoma; SMILE